Renal Cell Carcinoma Marker 腎細(xì)胞癌標(biāo)記

廣州健侖生物科技有限公司

RCC在90％以上原發(fā)性腎細(xì)胞癌,、 80％左右轉(zhuǎn)移性腎細(xì)胞癌陽(yáng)性表達(dá)。與CD10可聯(lián)合用于轉(zhuǎn)移性腎細(xì)胞癌的研究,。RCC還表達(dá)于乳腺腺泡和導(dǎo)管上皮細(xì)胞的腔面,、附睪上皮細(xì)胞及甲狀旁腺主細(xì)胞內(nèi)、甲狀腺濾泡內(nèi)的膠質(zhì),。

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱,、瘧疾、流感,、A鏈球菌,、合胞病毒、腮病毒,、乙腦,、寨卡、黃熱病,、基孔肯雅熱,、克錐蟲(chóng)病、違禁品濫用,、肺炎球菌,、軍團(tuán)菌、化妝品檢測(cè),、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清,、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品,。

歡迎咨詢

歡迎咨詢

Renal Cell Carcinoma Marker 腎細(xì)胞癌標(biāo)記

【產(chǎn)品介紹】

細(xì)胞定位：細(xì)胞漿/細(xì)胞膜

克隆號(hào)：66.4.C2

同型：IgG

適用組織：石蠟/冰凍

陽(yáng)性對(duì)照：腎細(xì)胞癌/正常腎

抗原修復(fù)：熱修復(fù)（EDTA）

抗體孵育時(shí)間：30-60min

想了解更多的產(chǎn)品及服務(wù)請(qǐng)掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場(chǎng)部】     歐

【】 
【騰訊  】 
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103室

近日,，來(lái)自牛津大學(xué)的科學(xué)家通過(guò)研究,，揭示了控制機(jī)體上皮細(xì)胞形狀和運(yùn)動(dòng)狀態(tài)發(fā)生轉(zhuǎn)變的關(guān)鍵機(jī)制，相關(guān)研究刊登于雜志Nature Cell biology上;文章中研究者表示,，名為ASPP2的腫瘤抑制蛋白的功能就好比是一種分子開(kāi)關(guān),，其可以控制并且逆轉(zhuǎn)機(jī)體上皮細(xì)胞的形狀及運(yùn)動(dòng)狀態(tài)的改變，這對(duì)于解釋一系列生化現(xiàn)象,，比如傷口愈合,、胚胎發(fā)育及癌癥轉(zhuǎn)移都非常關(guān)鍵。
研究者Xin Lu表示,，目前我們盡力去鑒別出控制控制上皮細(xì)胞可塑性的分子開(kāi)關(guān),，這樣的可塑性是癌癥的標(biāo)志，為了發(fā)生轉(zhuǎn)移,，癌細(xì)胞會(huì)疏松自身的結(jié)構(gòu),，不斷擺動(dòng)脫離母體腫瘤組織，進(jìn)而在機(jī)體其它組織器官部位“安家”,，上述的過(guò)程就稱為上皮細(xì)胞向間充質(zhì)細(xì)胞的轉(zhuǎn)分化過(guò)程及間質(zhì)細(xì)胞向上皮細(xì)胞的轉(zhuǎn)化過(guò)程(EMT及MET),。
研究者發(fā)現(xiàn)，在腎小管的發(fā)育過(guò)程中ASPP2蛋白會(huì)促使MET過(guò)程的發(fā)生,，從而過(guò)濾掉機(jī)體血液中的廢棄物,，而當(dāng)ASPP2蛋白缺失時(shí)會(huì)促進(jìn)EMT過(guò)程的發(fā)生，尤其是在表達(dá)常見(jiàn)癌癥基因RAS細(xì)胞中,，EMT過(guò)程尤為明顯,，從而就會(huì)引發(fā)癌癥發(fā)生轉(zhuǎn)移。隨后研究人員對(duì)小鼠模型進(jìn)行試驗(yàn)發(fā)現(xiàn),，當(dāng)小鼠機(jī)體中抗原抗體癌細(xì)胞表達(dá)較低水平的ASPP2時(shí),，其就會(huì)大量轉(zhuǎn)移至大腦細(xì)胞中，如果這些抗原抗體癌細(xì)胞表達(dá)較足量的ASPP2,，其轉(zhuǎn)移的能力就會(huì)明顯下降,。

Recently, scientists from Oxford University revealed the key mechanisms that control the change of the epithelial cell shape and movement in the body. Relevant research is published in the journal Nature Cell Biology. In the article, researchers said that the tumor suppressor protein called ASPP2 Is like a molecular switch that controls and reverses changes in the shape and motility of the body's epithelium, which is crucial for interpreting a range of biochemical phenomena such as wound healing, embryonic development, and cancer metastasis.
Xin Lu, a researcher, said that at present we try our best to identify molecular switches that control the plasticity of epithelial cells. Such plasticity is a hallmark of cancer. In order to metastasize, cancerous cells loose their structure and constantly swing away from the mother's tumor tissue, Other parts of the body organs "home", the above process is called the epithelial cells to mesenchymal cells transdifferentiation process and the conversion of stromal cells to epithelial cells (EMT and MET).
The researchers found that during the development of tubules, ASPP2 protein can promote the occurrence of MET process and thus filter out the body's blood waste, and when ASPP2 protein is missing, it can promote EMT process, especially in the expression of common cancer genes RAS cells, the EMT process is particularly evident, which will trigger the transfer of cancer. Subsequently, researchers conducted experiments on mouse models and found that when the antigen-antibody-expressing cancer cells in the mouse body express a lower level of ASPP2, they can be largely transferred to the brain cells. If these antigen-antibody-expressing cancer cells express a sufficient amount of ASPP2 , Its ability to transfer will be significantly reduced.